0001209191-24-000863.txt : 20240104
0001209191-24-000863.hdr.sgml : 20240104
20240104174031
ACCESSION NUMBER: 0001209191-24-000863
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lapetina Bob
CENTRAL INDEX KEY: 0002006639
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39580
FILM NUMBER: 24513510
MAIL ADDRESS:
STREET 1: C/O IMMUNONE, INC.
STREET 2: 665 STOCKTON DRIVE, SUITE 300
CITY: EXTON
STATE: PA
ZIP: 19341
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunome Inc.
CENTRAL INDEX KEY: 0001472012
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770694340
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 665 STOCKTON DRIVE
STREET 2: SUITE 300
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 610-321-3700
MAIL ADDRESS:
STREET 1: 665 STOCKTON DRIVE
STREET 2: SUITE 300
CITY: EXTON
STATE: PA
ZIP: 19341
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2024-01-02
0
0001472012
Immunome Inc.
IMNM
0002006639
Lapetina Bob
C/O IMMUNOME, INC.
665 STOCKTON DRIVE, SUITE 300
EXTON
PA
19341
0
1
0
0
PAO and VP Finance & Corporate
Common Stock
12047
D
Stock option (right to buy)
16.59
2031-05-11
Common Stock
11000
D
Stock option (right to buy)
20.92
2031-05-28
Common Stock
300
D
Stock option (right to buy)
3.42
2032-05-26
Common Stock
12000
D
Stock option (right to buy)
4.84
2033-06-08
Common Stock
17600
D
25% of the shares subject to the options vest on May 12, 2022, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
25% of the shares subject to the options vest on May 28, 2022, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
25% of the shares subject to the options vest on May 27, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
25% of the shares subject to the options vest on June 8, 2024, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
See Attached Exhibit 24
/s/ Sandra Stoneman, Attorney-in-fact
2024-01-04
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
(For Executing Form ID and Forms 3, 4 and 5)
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Clay B. Siegall and Sandra G. Stoneman of Immunome, Inc. (the
"Company"), signing individually, the undersigned's true and lawful attorneys-in
fact and agents to:
(1) Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC"), a Form ID and
Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in
connection therewith) in accordance with Section 16 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, in the
undersigned's capacity as an officer, director or beneficial owner of more than
10% of a registered class of securities of the Company;
(2) Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form ID and Forms
3, 4 or 5 (including amendments thereto and joint filing agreements in
connection therewith) and file such forms with the SEC and any stock exchange,
self-regulatory association or any similar authority; and
(3) Take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the Company and the foregoing attorneys-in fact or (c) as to any
attorney-in-fact individually, until such attorney-in-fact is no longer employed
by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.
Date: January 2, 2024
/s/ Bob Lapetina
Bob Lapetina